Ultragenyx Pharmaceutical | RARE - Equity Capital And Reserves


Ultragenyx Pharmaceutical reported $-291M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Immunic USD 151.23M 157.91M Mar/2026
Insmed USD 757.49M 52.64M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Kyowa Hakko Kirin JPY 916.17B 23.42B Jun/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Moderna USD 6.76B 647M Jun/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026